GlassScriptPhysician profile
John Frederick Norris
NPI 1689751901
$20,660.98
in general payments reported to CMS, 2019-2025
26 companies · $5,556 in 2025
The $5,556 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $496 · 2021: $293 · 2022: $374 · 2023: $1,322 · 2024: $2,511 · 2025: $5,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,303 · Travel and Lodging: $4,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,302.65 |
| Travel and Lodging | $4,085.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,178.74 | 2019-2025 | Farapulse, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $7,816.63 | 2019-2025 | |
| Medtronic, INC. | $1,838.03 | 2022-2025 | Mycarelink, Affera Mapping System, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $731.35 | 2019-2022 | |
| Biosense Webster, INC. | $327.64 | 2019-2025 | Carto 3, Nuvision Ice Catheter, Smartablatetm System Rf Generator |
| Medtronic Vascular, INC. | $278.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $230.74 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $164.59 | 2024-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $159.29 | 2024 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.90 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $128.85 | 2024-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $77.86 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $75.00 | 2019-2021 | |
| Cvrx, INC. | $68.34 | 2024-2025 | Barostim Neo System |
| Amgen INC. | $67.62 | 2020-2024 | Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $65.47 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $61.68 | 2022-2023 | |
| Bardy Diagnostics, INC. | $52.00 | 2019-2020 | |
| Esperion Therapeutics, INC. | $43.84 | 2025 | Nexletol |
| Cipher Pharmaceuticals US LLC | $36.08 | 2025 | Natroba, Spinosad |
| Glaxosmithkline, LLC. | $26.60 | 2025 | Shingrix, Arexvy |
| Cordis US Corp. | $20.42 | 2025 | Mynx Control Venous |
| Bayer Healthcare Pharmaceuticals INC. | $18.83 | 2025 | |
| Vektor Medical INC. | $14.26 | 2025 | Vmap |
| E.R. Squibb & Sons, L.L.C. | $13.54 | 2021 | |
| Altathera Pharmaceuticals LLC | $10.21 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.